Gilead wins approval for long-acting HIV injection after resolving vial concerns
Gilead finally gained FDA approval on Thursday for lenacapavir, its closely-watched capsid inhibitor for HIV-1, the most common type of HIV.
Lenacapavir will be marketed in the US as Sunlenca for heavily pretreated HIV-1 patients who are failing their current antiretroviral regimen. The long-acting subcutaneous injection is administered just twice a year, offering an alternative to cumbersome daily pill regimens.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.